We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

106 hedge funds and large institutions have $76.1M invested in Sanofi Contingent Value Rights in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

19% more capital invested

Capital invested by funds: $64M → $76.1M (+$12.1M)

6% more funds holding

Funds holding: 100106 (+6)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

Holders
106
Holders Change
+6
Holders Change %
+6%
% of All Funds
2.43%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
11
Reduced
16
Closed
8
Calls
$724K
Puts
Net Calls
+$724K
Net Calls Change
+$112K

GCVRZ Hedge Fund Activity: Q2 2018 in Review

106 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2018, worth a combined $76.1M — up 19% from $64M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GCVRZ positions and 8 closed out — a net gain of 7 holders — while 11 added to existing stakes and 16 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $304K. The largest seller was CSS LLC, cutting an estimated $71.2K.

  • 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2018, up from 100 in Q1 2018.
  • Funds reported $76.1M of Sanofi Contingent Value Rights stock for Q2 2018, up 19% quarter-over-quarter.
  • 15 funds opened new Sanofi Contingent Value Rights positions in Q2 2018 and 8 closed out, a net change of +7 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q2 2018 was Highbridge Capital Management, an estimated $304K added.
  • The largest Sanofi Contingent Value Rights seller in Q2 2018 was CSS LLC, an estimated $71.2K sold.

Based on aggregated 13F filings for Q2 2018.